Norovirus Prevention
Conditions
Keywords
Drug therapy
Brief summary
The purpose of this study is to evaluate the safety of the norovirus bivalent virus-like particle (VLP) vaccine for further development by assessing the rates of serious adverse events (SAEs), unsolicited adverse events (AEs), solicited local and solicited systemic AEs, Adverse Events of Special Interest (AESIs) and AEs leading to participant's withdrawal from the trial.
Detailed description
The vaccine being tested in this study is called norovirus GI.1/GII.4 bivalent virus-like particle (VLP) vaccine adjuvanted with or without monophosphoryl lipid A (MPL) and with aluminum hydroxide. The norovirus vaccine is being tested to provide additional safety and immunogenicity data to enable the vaccine to be further developed. This study will look at the side effects in people who take different formulations of the norovirus vaccine. The study will enroll approximately 450 participants. Participants will be randomly assigned (by chance, like flipping a coin) to one of the 3 treatment groups-which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need): * one dose of GI.1/GII.4 (15 µg/50 µg) adjuvanted with MPL (50 µg) and aluminum hydroxide (500 µg) on Day 1 followed by one dose of GI.1/GII.4 (15 µg/15 µg) adjuvanted with aluminum hydroxide (500 µg) (without MPL) on Day 365 * one dose of GI.1/GII.4 (50 µg/50 µg) adjuvanted with MPL (50 µg) and aluminum hydroxide (500 µg) on Day 1 followed by one dose of GI.1/GII.4 (15 µg/15 µg) adjuvanted with aluminum hydroxide (500 µg) (without MPL) on Day 365 * one dose of Saline Placebo (dummy inactive injection) - this is a liquid that has no active ingredient-on Day 1 + GI.1/GII.4 (15 µg/15 µg) adjuvanted with aluminum hydroxide (500 µg) (without MPL) as primary vaccination on Day 365 All participants will be administered vaccine or placebo on Day 1 of the study and will receive a vaccination dose (reduced antigen content) of the norovirus vaccine on Day 365. Participants will be asked to record any symptoms that may be related to the vaccine or the injection site in a diary card for 7 days after each vaccination. This multi-center trial will be conducted in the United States. The overall time to participate in this study is up to 18 months. Participants will make 11 visits to the clinic including a follow-up visit 6 months after the last dose of study medication.
Interventions
BIOLOGICALNorovirus Bivalent VLP Vaccine
Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with or without MPL and/or aluminum hydroxide IM injection
DRUGPlacebo (Saline)
Placebo-matching norovirus bivalent VLP vaccine
Sponsors
Takeda
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 49 Years
Healthy volunteers
Yes
Inclusion criteria
1. Male and female participants aged 18 to 49 years of age at the time of enrollment. 2. Are in good health at the time of entry into the trial as determined by medical history, physical examination and clinical judgment of the investigator. 3. Participants with a signed informed consent form and any required privacy authorization prior to the initiation of any trial procedures and after the nature of the trial has been explained according to local regulatory requirements. 4. Can comply with trial procedures and are available for the duration of the trial.
Exclusion criteria
1. Has a history of acute gastroenteritis within 14 days of enrollment. 2. Has a clinically significant active infection (as assessed by the investigator) or oral body temperature 38°C (100.4°F) or higher within 3 days of the intended date of vaccination. 3. Has received antipyretic/analgesic medications within 24 hours prior to the intended vaccine administration. 4. Has known hypersensitivity or allergy to any of the bivalent norovirus virus-like particle (VLP) vaccine components (including excipients of the investigational vaccines). 5. Has behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the participant's ability to participate in the trial. 6. Has a history of any progressive or severe neurologic disorder, seizure disorder, or neuro-inflammatory disease (e.g., Guillain-Barré syndrome). 7. Has history or any illness that, in the opinion of the investigator, might interfere with the results of the trial or pose additional risk to the participants due to participation in the trial. 8. Has known or suspected impairment/alteration of immune function including the following: 1. Chronic use of oral steroids (Equivalent to 20 mg/day prednisone for ≥ 12 weeks / ≥2 mg/kg body weight /day for ≥ 2 weeks) within 60 days prior to Day 1 (use of inhaled, intranasal, or topical corticosteroids is allowed). 2. Receipt of parenteral steroids (equivalent to 20 mg/day prednisone ≥ 12 weeks / ≥2 mg/kg body weight /day for ≥2 weeks) within 60 days prior to Day 1. 3. Receipt of immunostimulants within 60 days prior to Day 1. 4. Receipt of parenteral, epidural, or intra-articular immunoglobulin preparation, blood products, and/or plasma derivatives within 3 months prior to Day 1 or planned during the full length of the trial. 5. Receipt of immunosuppressive therapy within 6 months prior to Day 1. 6. Human immunodeficiency virus (HIV) infection or HIV-related disease. 7. Heritable immunodeficiency. 9. Has abnormalities of splenic or thymic function. 10. Has a history of any autoimmune disease. 11. Has a known bleeding diathesis or any condition that may be associated with a prolonged bleeding time. 12. Has any serious chronic or progressive disease according to judgment of the investigator (e.g., neoplasm, insulin dependent diabetes, cardiac, renal, or hepatic disease). 13. Has a body mass index (BMI) greater than or equal to 35 kg/m\^2 (= weight in kg / \[height in meters \* height in meters\]). 14. Is participating in any clinical trial with another investigational product 30 days prior to first trial visit or intent to participate in another clinical trial at any time during the conduct of this trial. 15. Participants who received any inactivated vaccines within 14 days or any live vaccines for 28 days prior to enrollment in this trial. 16. Are first degree relatives of individuals involved in trial conduct. 17. Has a history of substance or alcohol abuse within the past 2 years. 18. If female, of childbearing potential, sexually active, and has not used any of the acceptable contraceptive methods for at least 2 months prior to trial entry: 1. Of childbearing potential is defined as status post onset of menarche and not meeting any of the following conditions: menopausal for at least 2 years, status after bilateral tubal ligation for at least 1 year, status after bilateral oophorectomy, or status after hysterectomy. 2. Acceptable birth control methods are defined as 1 or more of the following: i. Hormonal contraceptive (such as oral, injection, transdermal patch, implant, cervical ring). ii. Barrier (condom with spermicide or diaphragm with spermicide) each and every time during intercourse. iii. Intrauterine device (IUD). iv. Monogamous relationship with vasectomized partner. Partner must have been vasectomized for at least 6 months prior to the participant's trial entry. 19. Female participants of childbearing potential and sexually active, who refuse to use an acceptable contraceptive method from Day 1 through 6 months after the last dose of investigational vaccine. 20. Female participants who plan to donate ova from Day 1 through 6 months after the last dose of investigational vaccine. 21. Female participants with any positive pregnancy test. 22. Female participants who are pregnant or breastfeeding.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the First Injection | Days 1 through 7 | Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occurred within 7 days after the primary injection. |
| Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the First Injection | Days 1 through 7 | Solicited systemic AEs are defined as: headache, fatigue, myalgia, arthralgia, vomiting, and diarrhea that occurred within 7 days after the primary injection. |
| Percentage of Participants With Elevated Daily Oral Temperature (Fever) After the First Injection | Days 1 through 7 | Fever is defined as greater than or equal to 38°C (100.4°F). Oral body temperature measurement was performed using the thermometer provided by the site for 7 days after each injection. The highest body temperature observed each day was recorded on the Diary Card also provided by the site. |
| Percentage of Participants With Unsolicited Adverse Events (AEs) After the First Injection | Days 1 through 28 | Unsolicited AEs are any AEs that are not solicited local or systemic AEs, as defined by this study. |
| Percentage of Participants With Serious Adverse Events (SAEs) After the First Injection | From first injection (Day 1) to second injection pre-dose (Up to Day 365) | A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. |
| Percentage of Participants With Serious Adverse Events (SAEs) After the Second Injection | From second injection (Day 365) to 6 months after second injection (Up to Day 545) | A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. |
| Percentage of Participants With Adverse Events of Special Interest (AESI) After the First Injection | From first injection (Day 1) to second injection pre-dose (Up to Day 365) | AESIs are AEs that are not solicited local or systemic AEs, they are predefined AEs that required close monitoring and prompt reporting to the sponsor. AESI included protocol specified Cardiac Disorders, Gastrointestinal Disorders, Immune System Disorders, Infections and Infestations, Musculoskeletal and Connective Tissue Diseases, Neuroinflammatory Disorders, Renal and Urinary Disorders, Skin Disorders, Thyroid Disorders, Vascular Disorders and Other Disorders. |
| Percentage of Participants With Adverse Events of Special Interest (AESI) After the Second Injection | From second injection (Day 365) to 6 months after second injection (Up to Day 545) | AESIs are AEs that are not solicited local or systemic AEs, they are predefined AEs that required close monitoring and prompt reporting to the sponsor. AESI included protocol specified Cardiac Disorders, Gastrointestinal Disorders, Immune System Disorders, Infections and Infestations, Musculoskeletal and Connective Tissue Diseases, Neuroinflammatory Disorders, Renal and Urinary Disorders, Skin Disorders, Thyroid Disorders, Vascular Disorders and Other Disorders. |
| Percentage of Participants With Any Adverse Event (AE) Leading to Withdrawal From the Study | Unsolicited AEs 28 days after each injection (Days 1 to 28 and Days 365 to 393), and Serious Adverse Events (SAEs) throughout the trial (Up to Day 545) | Withdrawal due to an AE occurred if the participant experienced an AE that required early termination because continued participation imposed an unacceptable risk to the participant's health or the participant was unwilling to continue because of the AE. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Geometric Mean Titer (GMT) of GI.1 VLP Antibody Titers (Pan-Ig ELISA) | Day 28 | Geometric mean titer (GMT) of anti-norovirus GI.1 VLP antibody titers as measured by Pan-Ig ELISA. |
| Geometric Mean Titer (GMT) of GII.4 VLP Antibody Titers (Pan-Ig ELISA) | Day 28 | Geometric mean titer (GMT) of anti-norovirus GII.4 VLP antibody titers as measured by Pan-Ig ELISA. |
| Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (Pan-Ig ELISA) | Day 28 | Geometric mean fold rise (GMFR) of anti-norovirus GI.1 VLP antibody titers as measured by Pan-Ig ELISA. |
| Percentage of Participants With a Seroresponse in Serum GI.1 VLP Antibody Titers (HBGA) | Baseline and Day 28 | Seroresponse is defined as 4-fold rise or greater in serum anti-norovirus antibody titers for GI.1 virus-Like particle (VLP) as measured by HBGA binding assay. |
| Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the Second Injection | Days 365 through 371 | Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occurred within 7 days after the vaccination on Day 365. |
| Blocking Titers 50 (BT50) of Anti-Norovirus GI.1 VLP Antibody Titers (HBGA) | Day 28 | Blocking titers 50 (BT50) of anti-norovirus GI.1 VLP antibody titers as measured by HBGA binding assay. |
| Blocking Titers 50 (BT50) of Anti-Norovirus GII.4 VLP Antibody Titers (HBGA) | Day 28 | Blocking titers 50 (BT50) of anti-norovirus GII.4 VLP antibody titers as measured by HBGA binding assay. |
| Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (HBGA) | Day 28 | Geometric mean fold rise (GMFR) of anti-norovirus GI.1 VLP antibody titers as measured by HBGA binding assay. |
| Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (HBGA) | Day 28 | Geometric mean fold rise (GMFR) of anti-norovirus GII.4 VLP antibody titers as measured by the HBGA binding assay. |
| Percentage of Participants With a Seroresponse in Serum GII.4 VLP Antibody Titers (HBGA) | Baseline and Day 28 | Seroresponse is defined as 4-fold rise or greater in serum anti-norovirus antibody titers for GII.4 virus-Like particle (VLP) as measured by HBGA binding assay. |
| Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the Second Injection | Days 365 through 371 | Solicited systemic AEs are defined as: headache, fatigue, myalgia, arthralgia, vomiting, and diarrhea that occurred within 7 days after the vaccination on Day 365. |
| Percentage of Participants With Elevated Daily Oral Temperature (Fever) After the Second Injection | Days 365 through 371 | Fever is defined as greater than or equal to 38°C (100.4°F). Oral body temperature measurement was performed using the thermometer provided by the site for 7 days after each vaccination. The highest body temperature observed each day was recorded on the Diary Card also provided by the site. |
| Percentage of Participants With Unsolicited Adverse Events (AEs) After the Second Injection | Days 365 through 393 | Unsolicited AEs are any AEs that are not solicited local or systemic AEs, as defined by this study. |
| Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (Pan-Ig ELISA) | Day 28 | Geometric mean fold rise (GMFR) of anti-norovirus GII.4 VLP antibody titers as measured by Pan-Ig ELISA. |
| Percentage of Participants With a Seroresponse in Both Serum Anti-norovirus GI.1 VLP and GII.4 VLP (HBGA) | Baseline and Day 28 | Seroresponse is defined as 4-fold rise or greater in serum anti-norovirus antibody titers for both GI.1 virus-Like particle (VLP) and GII.4 VLP as measured by histoblood group antigen (HBGA) binding assay. |
| Percentage of Participants With a Seroresponse in Both Serum Anti-norovirus GI.1 VLP and GII.4 VLP (Pan-Ig ELISA) | Baseline and Day 28 | Seroresponse is defined as 4-fold rise or greater in serum anti-norovirus antibody titers for both GI.1 virus-Like particle (VLP) and GII.4 VLP as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA). |
| Percentage of Participants With a Seroresponse in Serum Anti-norovirus GI.1 VLP (Pan-Ig ELISA) | Baseline and Day 28 | Seroresponse is defined as 4-fold rise or greater in serum anti-norovirus antibody titers for GI.1 virus-Like particle (VLP) as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA). |
| Percentage of Participants With a Seroresponse in Serum Anti-norovirus GII.4 VLP (Pan-Ig ELISA) | Baseline and Day 28 | Seroresponse is defined as 4-fold rise or greater in serum anti-norovirus antibody titers for GII.4 virus-like particles (VLP) as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA). |
Countries
United States
Participant flow
Recruitment details
Participants took part in the study at 10 investigative sites in the United States from 28 April 2014 to 14 January 2016.
Pre-assignment details
Healthy volunteers were enrolled equally in 1 of 3 norovirus bivalent virus like particle (VLP) vaccine unique formulation treatment groups to receive: 2 formulation arms received 2 doses and 1 formulation arm received 1 dose.
Participants by arm
| Arm | Count |
|---|---|
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) Intramuscular (IM) saline placebo on Day 1, followed by IM norovirus bivalent virus like particle (VLP) vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide (no monophosphoryl lipid A \[MPL\]), on Day 365. | 153 |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) IM norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MPL and 500 µg aluminum hydroxide, on Day 1, followed by IM norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, (no MPL) on Day 365. | 147 |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) IM norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MPL and 500 µg aluminum hydroxide, on Day 1, followed by IM norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide (no MPL), on Day 365. | 154 |
| Total | 454 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Adverse Event | 2 | 3 | 4 |
| Overall Study | Lost to Follow-up | 12 | 19 | 17 |
| Overall Study | Physician Decision | 0 | 1 | 3 |
| Overall Study | Pregnancy | 4 | 4 | 2 |
| Overall Study | Protocol Violation | 2 | 1 | 2 |
| Overall Study | Reason Not Specified | 4 | 5 | 4 |
| Overall Study | Withdrawal by Subject | 7 | 9 | 11 |
Baseline characteristics
| Characteristic | GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Total | Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) |
|---|---|---|---|---|
| Age, Continuous | 33.4 years STANDARD_DEVIATION 9.26 | 33.5 years STANDARD_DEVIATION 8.96 | 32.9 years STANDARD_DEVIATION 8.87 | 34.0 years STANDARD_DEVIATION 8.78 |
| Body Mass Index (BMI) | 26.44 kg/m^2 STANDARD_DEVIATION 4.427 | 26.32 kg/m^2 STANDARD_DEVIATION 4.281 | 26.40 kg/m^2 STANDARD_DEVIATION 4.125 | 26.14 kg/m^2 STANDARD_DEVIATION 4.313 |
| Height | 168.89 cm STANDARD_DEVIATION 9.67 | 170.03 cm STANDARD_DEVIATION 9.616 | 169.91 cm STANDARD_DEVIATION 9.228 | 171.24 cm STANDARD_DEVIATION 9.859 |
| Race/Ethnicity, Customized American Indian or Alaska Native | 0 participants | 2 participants | 0 participants | 2 participants |
| Race/Ethnicity, Customized Asian | 3 participants | 10 participants | 5 participants | 2 participants |
| Race/Ethnicity, Customized Black or African American | 49 participants | 137 participants | 41 participants | 47 participants |
| Race/Ethnicity, Customized Hispanic or Latino | 38 participants | 118 participants | 34 participants | 46 participants |
| Race/Ethnicity, Customized Multiracial | 1 participants | 9 participants | 3 participants | 5 participants |
| Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander | 2 participants | 7 participants | 3 participants | 2 participants |
| Race/Ethnicity, Customized Non-Hispanic and Latino | 109 participants | 333 participants | 117 participants | 107 participants |
| Race/Ethnicity, Customized Not Reported | 0 participants | 2 participants | 1 participants | 1 participants |
| Race/Ethnicity, Customized Other | 1 participants | 4 participants | 1 participants | 2 participants |
| Race/Ethnicity, Customized Unknown | 0 participants | 1 participants | 1 participants | 0 participants |
| Race/Ethnicity, Customized White | 91 participants | 285 participants | 100 participants | 94 participants |
| Region of Enrollment United States | 147 participants | 454 participants | 153 participants | 154 participants |
| Sex: Female, Male Female | 89 Participants | 253 Participants | 89 Participants | 75 Participants |
| Sex: Female, Male Male | 58 Participants | 201 Participants | 64 Participants | 79 Participants |
| Weight | 75.56 kg STANDARD_DEVIATION 14.72 | 76.33 kg STANDARD_DEVIATION 15.068 | 76.50 kg STANDARD_DEVIATION 14.924 | 76.91 kg STANDARD_DEVIATION 15.598 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 33 / 153 | 24 / 145 | 25 / 154 |
| serious Total, serious adverse events | 4 / 153 | 4 / 145 | 6 / 154 |
Outcome results
Primary
Percentage of Participants With Adverse Events of Special Interest (AESI) After the First Injection
AESIs are AEs that are not solicited local or systemic AEs, they are predefined AEs that required close monitoring and prompt reporting to the sponsor. AESI included protocol specified Cardiac Disorders, Gastrointestinal Disorders, Immune System Disorders, Infections and Infestations, Musculoskeletal and Connective Tissue Diseases, Neuroinflammatory Disorders, Renal and Urinary Disorders, Skin Disorders, Thyroid Disorders, Vascular Disorders and Other Disorders.
Time frame: From first injection (Day 1) to second injection pre-dose (Up to Day 365)
Population: Safety Analysis Set included all participants who received at least one dose of trial vaccination.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With Adverse Events of Special Interest (AESI) After the First Injection | 1.3 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Adverse Events of Special Interest (AESI) After the First Injection | 2.1 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Adverse Events of Special Interest (AESI) After the First Injection | 1.3 percentage of participants |
Primary
Percentage of Participants With Adverse Events of Special Interest (AESI) After the Second Injection
AESIs are AEs that are not solicited local or systemic AEs, they are predefined AEs that required close monitoring and prompt reporting to the sponsor. AESI included protocol specified Cardiac Disorders, Gastrointestinal Disorders, Immune System Disorders, Infections and Infestations, Musculoskeletal and Connective Tissue Diseases, Neuroinflammatory Disorders, Renal and Urinary Disorders, Skin Disorders, Thyroid Disorders, Vascular Disorders and Other Disorders.
Time frame: From second injection (Day 365) to 6 months after second injection (Up to Day 545)
Population: Participants from the Safety Analysis Set who received a second injection.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With Adverse Events of Special Interest (AESI) After the Second Injection | 3.2 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Adverse Events of Special Interest (AESI) After the Second Injection | 0 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Adverse Events of Special Interest (AESI) After the Second Injection | 0.9 percentage of participants |
Primary
Percentage of Participants With Any Adverse Event (AE) Leading to Withdrawal From the Study
Withdrawal due to an AE occurred if the participant experienced an AE that required early termination because continued participation imposed an unacceptable risk to the participant's health or the participant was unwilling to continue because of the AE.
Time frame: Unsolicited AEs 28 days after each injection (Days 1 to 28 and Days 365 to 393), and Serious Adverse Events (SAEs) throughout the trial (Up to Day 545)
Population: Safety Analysis Set included all participants who received at least one dose of trial vaccination.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With Any Adverse Event (AE) Leading to Withdrawal From the Study | 1.3 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Any Adverse Event (AE) Leading to Withdrawal From the Study | 1.4 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Any Adverse Event (AE) Leading to Withdrawal From the Study | 2.6 percentage of participants |
Primary
Percentage of Participants With Elevated Daily Oral Temperature (Fever) After the First Injection
Fever is defined as greater than or equal to 38°C (100.4°F). Oral body temperature measurement was performed using the thermometer provided by the site for 7 days after each injection. The highest body temperature observed each day was recorded on the Diary Card also provided by the site.
Time frame: Days 1 through 7
Population: Safety Analysis Set included all participants who received at least one dose of trial vaccination.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With Elevated Daily Oral Temperature (Fever) After the First Injection | 0 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Elevated Daily Oral Temperature (Fever) After the First Injection | 0.7 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Elevated Daily Oral Temperature (Fever) After the First Injection | 0 percentage of participants |
Primary
Percentage of Participants With Serious Adverse Events (SAEs) After the First Injection
A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.
Time frame: From first injection (Day 1) to second injection pre-dose (Up to Day 365)
Population: Safety Analysis Set included all participants who received at least one dose of trial vaccination.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With Serious Adverse Events (SAEs) After the First Injection | 1.3 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Serious Adverse Events (SAEs) After the First Injection | 2.1 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Serious Adverse Events (SAEs) After the First Injection | 3.2 percentage of participants |
Primary
Percentage of Participants With Serious Adverse Events (SAEs) After the Second Injection
A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.
Time frame: From second injection (Day 365) to 6 months after second injection (Up to Day 545)
Population: Participants from the Safety Analysis Set who received a second injection.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With Serious Adverse Events (SAEs) After the Second Injection | 1.6 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Serious Adverse Events (SAEs) After the Second Injection | 0.9 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Serious Adverse Events (SAEs) After the Second Injection | 0.9 percentage of participants |
Primary
Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the First Injection
Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occurred within 7 days after the primary injection.
Time frame: Days 1 through 7
Population: Safety Analysis Set included all participants who received at least one dose of trial vaccination.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the First Injection | Pain | 7.8 percentage of participants |
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the First Injection | Any Solicited Local AEs | 7.8 percentage of participants |
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the First Injection | Erythema | 0 percentage of participants |
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the First Injection | Induration | 0 percentage of participants |
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the First Injection | Swelling | 0 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the First Injection | Induration | 1.4 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the First Injection | Pain | 64.1 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the First Injection | Swelling | 2.1 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the First Injection | Erythema | 0 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the First Injection | Any Solicited Local AEs | 64.1 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the First Injection | Induration | 1.3 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the First Injection | Any Solicited Local AEs | 72.7 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the First Injection | Pain | 72.7 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the First Injection | Erythema | 0.6 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the First Injection | Swelling | 0.6 percentage of participants |
Primary
Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the First Injection
Solicited systemic AEs are defined as: headache, fatigue, myalgia, arthralgia, vomiting, and diarrhea that occurred within 7 days after the primary injection.
Time frame: Days 1 through 7
Population: Safety Analysis Set included all participants who received at least one dose of trial vaccination.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the First Injection | Headache | 16.3 percentage of participants |
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the First Injection | Vomiting | 1.3 percentage of participants |
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the First Injection | Diarrhea | 7.8 percentage of participants |
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the First Injection | Fatigue | 17.0 percentage of participants |
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the First Injection | Any Solicited Systemic AEs | 26.8 percentage of participants |
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the First Injection | Myalgia | 7.2 percentage of participants |
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the First Injection | Arthralgia | 3.3 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the First Injection | Arthralgia | 4.8 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the First Injection | Fatigue | 15.9 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the First Injection | Vomiting | 1.4 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the First Injection | Headache | 15.9 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the First Injection | Myalgia | 19.3 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the First Injection | Diarrhea | 7.6 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the First Injection | Any Solicited Systemic AEs | 33.1 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the First Injection | Diarrhea | 10.4 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the First Injection | Any Solicited Systemic AEs | 45.5 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the First Injection | Headache | 18.2 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the First Injection | Fatigue | 16.2 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the First Injection | Arthralgia | 7.8 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the First Injection | Vomiting | 1.9 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the First Injection | Myalgia | 25.3 percentage of participants |
Primary
Percentage of Participants With Unsolicited Adverse Events (AEs) After the First Injection
Unsolicited AEs are any AEs that are not solicited local or systemic AEs, as defined by this study.
Time frame: Days 1 through 28
Population: Safety Analysis Set included all participants who received at least one dose of trial vaccination.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With Unsolicited Adverse Events (AEs) After the First Injection | 23.5 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Unsolicited Adverse Events (AEs) After the First Injection | 16.6 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Unsolicited Adverse Events (AEs) After the First Injection | 21.4 percentage of participants |
Secondary
Blocking Titers 50 (BT50) of Anti-Norovirus GI.1 VLP Antibody Titers (HBGA)
Blocking titers 50 (BT50) of anti-norovirus GI.1 VLP antibody titers as measured by HBGA binding assay.
Time frame: Day 28
Population: Per Protocol Set included all participants in Full Analysis Set, who had evaluable blood samples at baseline, and Day 28 within the specified window (+/- 7 days), and did not have major protocol violations.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Blocking Titers 50 (BT50) of Anti-Norovirus GI.1 VLP Antibody Titers (HBGA) | 20.7 titer | Standard Deviation 2.38 |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Blocking Titers 50 (BT50) of Anti-Norovirus GI.1 VLP Antibody Titers (HBGA) | 170.9 titer | Standard Deviation 3.9 |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Blocking Titers 50 (BT50) of Anti-Norovirus GI.1 VLP Antibody Titers (HBGA) | 207.8 titer | Standard Deviation 3.94 |
Secondary
Blocking Titers 50 (BT50) of Anti-Norovirus GII.4 VLP Antibody Titers (HBGA)
Blocking titers 50 (BT50) of anti-norovirus GII.4 VLP antibody titers as measured by HBGA binding assay.
Time frame: Day 28
Population: Participants from the Per Protocol Set, all participants in Full Analysis Set, who had evaluable blood samples at baseline, and Day 28 within the specified window (+/- 7 days), and did not have major protocol violations, with data available for this outcome measure.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Blocking Titers 50 (BT50) of Anti-Norovirus GII.4 VLP Antibody Titers (HBGA) | 80.1 titer | Standard Deviation 4.33 |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Blocking Titers 50 (BT50) of Anti-Norovirus GII.4 VLP Antibody Titers (HBGA) | 804.3 titer | Standard Deviation 3.32 |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Blocking Titers 50 (BT50) of Anti-Norovirus GII.4 VLP Antibody Titers (HBGA) | 631.3 titer | Standard Deviation 3.05 |
Secondary
Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (HBGA)
Geometric mean fold rise (GMFR) of anti-norovirus GI.1 VLP antibody titers as measured by HBGA binding assay.
Time frame: Day 28
Population: Per Protocol Set included all participants in Full Analysis Set, who had evaluable blood samples at baseline, and Day 28 within the specified window (+/- 7 days), and did not have major protocol violations.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (HBGA) | 1.1 ratio | Standard Deviation 1.69 |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (HBGA) | 8.9 ratio | Standard Deviation 3.64 |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (HBGA) | 10.5 ratio | Standard Deviation 3.56 |
Secondary
Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (Pan-Ig ELISA)
Geometric mean fold rise (GMFR) of anti-norovirus GI.1 VLP antibody titers as measured by Pan-Ig ELISA.
Time frame: Day 28
Population: Per Protocol Set included all participants in Full Analysis Set, who had evaluable blood samples at baseline, and Day 28 within the specified window (+/- 7 days), and did not have major protocol violations.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (Pan-Ig ELISA) | 1.3 ratio | Standard Deviation 3.81 |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (Pan-Ig ELISA) | 37.6 ratio | Standard Deviation 6.11 |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (Pan-Ig ELISA) | 55.9 ratio | Standard Deviation 5.9 |
Secondary
Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (HBGA)
Geometric mean fold rise (GMFR) of anti-norovirus GII.4 VLP antibody titers as measured by the HBGA binding assay.
Time frame: Day 28
Population: Participants from the Per Protocol Set, all participants in Full Analysis Set, who had evaluable blood samples at baseline, and Day 28 within the specified window (+/- 7 days), and did not have major protocol violations, with data available for this outcome measure.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (HBGA) | 1.0 ratio | Standard Deviation 1.77 |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (HBGA) | 9.7 ratio | Standard Deviation 4.03 |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (HBGA) | 7.3 ratio | Standard Deviation 3.23 |
Secondary
Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (Pan-Ig ELISA)
Geometric mean fold rise (GMFR) of anti-norovirus GII.4 VLP antibody titers as measured by Pan-Ig ELISA.
Time frame: Day 28
Population: Per Protocol Set included all participants in Full Analysis Set, who had evaluable blood samples at baseline, and Day 28 within the specified window (+/- 7 days), and did not have major protocol violations.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (Pan-Ig ELISA) | 1.1 ratio | Standard Deviation 2.08 |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (Pan-Ig ELISA) | 10.7 ratio | Standard Deviation 4.35 |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (Pan-Ig ELISA) | 7.4 ratio | Standard Deviation 3.46 |
Secondary
Geometric Mean Titer (GMT) of GI.1 VLP Antibody Titers (Pan-Ig ELISA)
Geometric mean titer (GMT) of anti-norovirus GI.1 VLP antibody titers as measured by Pan-Ig ELISA.
Time frame: Day 28
Population: Per Protocol Set included all participants in Full Analysis Set, who had evaluable blood samples at baseline, and Day 28 within the specified window (+/- 7 days), and did not have major protocol violations.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Geometric Mean Titer (GMT) of GI.1 VLP Antibody Titers (Pan-Ig ELISA) | 366.8 titer | Standard Deviation 6.29 |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Geometric Mean Titer (GMT) of GI.1 VLP Antibody Titers (Pan-Ig ELISA) | 13023.2 titer | Standard Deviation 3.4 |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Geometric Mean Titer (GMT) of GI.1 VLP Antibody Titers (Pan-Ig ELISA) | 18711.8 titer | Standard Deviation 3.84 |
Secondary
Geometric Mean Titer (GMT) of GII.4 VLP Antibody Titers (Pan-Ig ELISA)
Geometric mean titer (GMT) of anti-norovirus GII.4 VLP antibody titers as measured by Pan-Ig ELISA.
Time frame: Day 28
Population: Per Protocol Set included all participants in Full Analysis Set, who had evaluable blood samples at baseline, and Day 28 within the specified window (+/- 7 days), and did not have major protocol violations.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Geometric Mean Titer (GMT) of GII.4 VLP Antibody Titers (Pan-Ig ELISA) | 955.5 titer | Standard Deviation 5.08 |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Geometric Mean Titer (GMT) of GII.4 VLP Antibody Titers (Pan-Ig ELISA) | 11275.5 titer | Standard Deviation 2.38 |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Geometric Mean Titer (GMT) of GII.4 VLP Antibody Titers (Pan-Ig ELISA) | 8667.9 titer | Standard Deviation 2.84 |
Secondary
Percentage of Participants With a Seroresponse in Both Serum Anti-norovirus GI.1 VLP and GII.4 VLP (HBGA)
Seroresponse is defined as 4-fold rise or greater in serum anti-norovirus antibody titers for both GI.1 virus-Like particle (VLP) and GII.4 VLP as measured by histoblood group antigen (HBGA) binding assay.
Time frame: Baseline and Day 28
Population: Participants from the Per Protocol Set, all participants in Full Analysis Set, who had evaluable blood samples at baseline, and Day 28 within the specified window (+/- 7 days), and did not have major protocol violations, with data available for this outcome measure.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With a Seroresponse in Both Serum Anti-norovirus GI.1 VLP and GII.4 VLP (HBGA) | 2.0 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With a Seroresponse in Both Serum Anti-norovirus GI.1 VLP and GII.4 VLP (HBGA) | 55.4 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With a Seroresponse in Both Serum Anti-norovirus GI.1 VLP and GII.4 VLP (HBGA) | 55.0 percentage of participants |
Secondary
Percentage of Participants With a Seroresponse in Both Serum Anti-norovirus GI.1 VLP and GII.4 VLP (Pan-Ig ELISA)
Seroresponse is defined as 4-fold rise or greater in serum anti-norovirus antibody titers for both GI.1 virus-Like particle (VLP) and GII.4 VLP as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).
Time frame: Baseline and Day 28
Population: Per Protocol Set included all participants in Full Analysis Set, who had evaluable blood samples at baseline, and Day 28 within the specified window (+/- 7 days), and did not have major protocol violations.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With a Seroresponse in Both Serum Anti-norovirus GI.1 VLP and GII.4 VLP (Pan-Ig ELISA) | 2.6 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With a Seroresponse in Both Serum Anti-norovirus GI.1 VLP and GII.4 VLP (Pan-Ig ELISA) | 70.7 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With a Seroresponse in Both Serum Anti-norovirus GI.1 VLP and GII.4 VLP (Pan-Ig ELISA) | 64.9 percentage of participants |
Secondary
Percentage of Participants With a Seroresponse in Serum Anti-norovirus GI.1 VLP (Pan-Ig ELISA)
Seroresponse is defined as 4-fold rise or greater in serum anti-norovirus antibody titers for GI.1 virus-Like particle (VLP) as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).
Time frame: Baseline and Day 28
Population: Per Protocol Set included all participants in Full Analysis Set, who had evaluable blood samples at baseline, and Day 28 within the specified window (+/- 7 days), and did not have major protocol violations.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With a Seroresponse in Serum Anti-norovirus GI.1 VLP (Pan-Ig ELISA) | 8.6 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With a Seroresponse in Serum Anti-norovirus GI.1 VLP (Pan-Ig ELISA) | 91.4 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With a Seroresponse in Serum Anti-norovirus GI.1 VLP (Pan-Ig ELISA) | 90.1 percentage of participants |
Secondary
Percentage of Participants With a Seroresponse in Serum Anti-norovirus GII.4 VLP (Pan-Ig ELISA)
Seroresponse is defined as 4-fold rise or greater in serum anti-norovirus antibody titers for GII.4 virus-like particles (VLP) as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).
Time frame: Baseline and Day 28
Population: Per Protocol Set included all participants in Full Analysis Set, who had evaluable blood samples at baseline, and Day 28 within the specified window (+/- 7 days), and did not have major protocol violations.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With a Seroresponse in Serum Anti-norovirus GII.4 VLP (Pan-Ig ELISA) | 4.6 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With a Seroresponse in Serum Anti-norovirus GII.4 VLP (Pan-Ig ELISA) | 75.0 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With a Seroresponse in Serum Anti-norovirus GII.4 VLP (Pan-Ig ELISA) | 69.5 percentage of participants |
Secondary
Percentage of Participants With a Seroresponse in Serum GI.1 VLP Antibody Titers (HBGA)
Seroresponse is defined as 4-fold rise or greater in serum anti-norovirus antibody titers for GI.1 virus-Like particle (VLP) as measured by HBGA binding assay.
Time frame: Baseline and Day 28
Population: Per Protocol Set included all participants in Full Analysis Set, who had evaluable blood samples at baseline, and Day 28 within the specified window (+/- 7 days), and did not have major protocol violations.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With a Seroresponse in Serum GI.1 VLP Antibody Titers (HBGA) | 3.3 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With a Seroresponse in Serum GI.1 VLP Antibody Titers (HBGA) | 74.3 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With a Seroresponse in Serum GI.1 VLP Antibody Titers (HBGA) | 80.8 percentage of participants |
Secondary
Percentage of Participants With a Seroresponse in Serum GII.4 VLP Antibody Titers (HBGA)
Seroresponse is defined as 4-fold rise or greater in serum anti-norovirus antibody titers for GII.4 virus-Like particle (VLP) as measured by HBGA binding assay.
Time frame: Baseline and Day 28
Population: Participants from the Per Protocol Set, all participants in Full Analysis Set, who had evaluable blood samples at baseline, and Day 28 within the specified window (+/- 7 days), and did not have major protocol violations, with data for this outcome measure
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With a Seroresponse in Serum GII.4 VLP Antibody Titers (HBGA) | 2.6 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With a Seroresponse in Serum GII.4 VLP Antibody Titers (HBGA) | 71.2 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With a Seroresponse in Serum GII.4 VLP Antibody Titers (HBGA) | 68.2 percentage of participants |
Secondary
Percentage of Participants With Elevated Daily Oral Temperature (Fever) After the Second Injection
Fever is defined as greater than or equal to 38°C (100.4°F). Oral body temperature measurement was performed using the thermometer provided by the site for 7 days after each vaccination. The highest body temperature observed each day was recorded on the Diary Card also provided by the site.
Time frame: Days 365 through 371
Population: Participants from the Safety Analysis Set who received a second injection.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With Elevated Daily Oral Temperature (Fever) After the Second Injection | 0 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Elevated Daily Oral Temperature (Fever) After the Second Injection | 0.9 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Elevated Daily Oral Temperature (Fever) After the Second Injection | 2.6 percentage of participants |
Secondary
Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the Second Injection
Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occurred within 7 days after the vaccination on Day 365.
Time frame: Days 365 through 371
Population: Participants from the Safety Analysis Set who received a second injection.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the Second Injection | Induration | 0 percentage of participants |
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the Second Injection | Erythema | 0.8 percentage of participants |
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the Second Injection | Any Solicited Local AEs | 41.3 percentage of participants |
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the Second Injection | Pain | 41.3 percentage of participants |
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the Second Injection | Swelling | 0 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the Second Injection | Any Solicited Local AEs | 41.3 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the Second Injection | Pain | 41.3 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the Second Injection | Erythema | 0.9 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the Second Injection | Induration | 0 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the Second Injection | Swelling | 2.8 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the Second Injection | Swelling | 0 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the Second Injection | Induration | 0 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the Second Injection | Any Solicited Local AEs | 44.0 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the Second Injection | Erythema | 0 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the Second Injection | Pain | 44.0 percentage of participants |
Secondary
Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the Second Injection
Solicited systemic AEs are defined as: headache, fatigue, myalgia, arthralgia, vomiting, and diarrhea that occurred within 7 days after the vaccination on Day 365.
Time frame: Days 365 through 371
Population: Participants from the Safety Analysis Set who received a second injection.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the Second Injection | Headache | 11.9 percentage of participants |
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the Second Injection | Arthralgia | 0.8 percentage of participants |
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the Second Injection | Myalgia | 15.1 percentage of participants |
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the Second Injection | Any Solicited Systemic AEs | 28.6 percentage of participants |
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the Second Injection | Diarrhea | 4.0 percentage of participants |
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the Second Injection | Vomiting | 2.4 percentage of participants |
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the Second Injection | Fatigue | 11.1 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the Second Injection | Myalgia | 15.6 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the Second Injection | Any Solicited Systemic AEs | 25.7 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the Second Injection | Headache | 11.0 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the Second Injection | Fatigue | 14.7 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the Second Injection | Arthralgia | 7.3 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the Second Injection | Vomiting | 1.8 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the Second Injection | Diarrhea | 7.3 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the Second Injection | Arthralgia | 6.0 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the Second Injection | Headache | 14.7 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the Second Injection | Diarrhea | 8.6 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the Second Injection | Vomiting | 1.7 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the Second Injection | Myalgia | 14.7 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the Second Injection | Fatigue | 17.2 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Solicited Systemic Adverse Events (AEs) After the Second Injection | Any Solicited Systemic AEs | 31.9 percentage of participants |
Secondary
Percentage of Participants With Unsolicited Adverse Events (AEs) After the Second Injection
Unsolicited AEs are any AEs that are not solicited local or systemic AEs, as defined by this study.
Time frame: Days 365 through 393
Population: Participants from the Safety Analysis Set who received a second injection.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Saline Placebo + GI.1/GII.4 15/15 μg (No MPL) | Percentage of Participants With Unsolicited Adverse Events (AEs) After the Second Injection | 20.6 percentage of participants |
| GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Unsolicited Adverse Events (AEs) After the Second Injection | 14.7 percentage of participants |
| GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL) | Percentage of Participants With Unsolicited Adverse Events (AEs) After the Second Injection | 14.7 percentage of participants |